Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Current medical treatment of pulmonary arterial hypertension
Roxana Sulica, Michael Poon
Icahn School of Medicine at Mount Sinai
Research output
:
Contribution to journal
›
Review article
›
peer-review
12
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current medical treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Medical Treatment
100%
Pulmonary Arterial Hypertension
100%
Primary Pulmonary Hypertension
60%
Right Heart Catheterization
40%
Etiology
20%
Risk Factors
20%
Therapeutic Target
20%
Median Survival
20%
Treatment Strategy
20%
Disease Severity
20%
Clinical Research
20%
Inappropriate Treatment
20%
Disease Course
20%
Anticoagulants
20%
Conventional Treatment
20%
Illness
20%
New Targets
20%
Clinical Conditions
20%
Survival Benefit
20%
Natural Course
20%
Vasodilator
20%
Therapeutic Decision-making
20%
Rare Diseases
20%
Valuable Insight
20%
Calcium Channel Blockers
20%
Right Heart Failure
20%
Pulmonary Hypertension
20%
Syncope
20%
Functional Impairment
20%
Combination Treatment
20%
Graves
20%
Hemodynamic Response
20%
Specific Treatment
20%
Diuretics
20%
Pulmonary Vasculature
20%
Functional Benefit
20%
Oxygen Supplementation
20%
Dyspnea on Exertion
20%
Vasoreactivity
20%
Epoprostenol
20%
Oral Calcium
20%
Inotropic Medications
20%
Bosentan
20%
Functional Hemodynamics
20%
Treprostinil
20%
Medicine and Dentistry
Combination Therapy
100%
Pulmonary Hypertension
100%
Disease
22%
Cardiac Catheterization
22%
Dyspnea
11%
Drug Therapy
11%
Exercise
11%
Supplementation
11%
Disease Severity
11%
Hemodynamic
11%
Clinical Research
11%
Heart Right Ventricle Failure
11%
Prostacyclin
11%
Hope
11%
Vasodilator Agent
11%
Physical Disease by Body Function
11%
Rare Disease
11%
Calcium Channel Blocking Agent
11%
Inotropism
11%
Anticoagulant
11%
Faintness
11%
Diuretic Agent
11%
Functional Disease
11%
Pulmonary Vasculature
11%
Treprostinil
11%
Bosentan
11%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Pulmonary Hypertension
100%
Disease
22%
Dyspnea
11%
Anticoagulant Agent
11%
Clinical Research
11%
Prostacyclin
11%
Vasodilator Agent
11%
Disease Severity
11%
Physical Disease by Body Function
11%
Rare Disease
11%
Calcium Channel Blocker
11%
Functional Disease
11%
Faintness
11%
Diuretic Agent
11%
Heart Right Ventricle Failure
11%
Treprostinil
11%
Bosentan
11%